Velocity Fund launches InClinica from acquired CRO IndiPharm


Pittsburgh’s Velocity Fund Partners has picked up CRO IndiPharm for an undisclosed amount, renaming the Philadelphia firm InClinica.

InClinica, as it is now called, boasts a specialty in early and midstage trials from Pennsylvania, and it also has locations in the U.K., Israel, Malaysia and Singapore. Velocity is looking to cash in on this global reach, positioning the CRO for growth down the road, according to a release.

With the acquisition, IndiPharm founder and president Edward Brennan will serve as InClinica’s chief medical officer, and Michael Fare will be chief operating officer and chief technical officer.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Bloomberg writes in an overview that one of Indipharm’s strategies is to provide Western biopharmas “a gateway for conducting clinical trials in India.” Currently, the company is managing a global Phase III clinical trial for lung cancer.

“InClinica’s existing global footprint and experience in early drug and device development and clinical trials, combined with Velocity’s unique experience and contacts in both healthcare and life sciences, will enable InClinica to provide companies with significant value in all clinical phases,” said Velocity Managing Partner Ken Melani.

“Many drugs fail to advance during clinical research for reasons unrelated to efficacy or safety,” Fare said. “An experienced clinical CRO can anticipate challenges and plan ahead, ensuring a smoother progression through clinical development.”

- here's the release

Related Article:
WCCT Global and cancer CRO Medelis to combine under merger deal


Suggested Articles

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.

Computing-enabled R&D shop Schrödinger will use its $110 million haul to advance its nascent pipeline of wholly owned drugs.